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How proliferative and inhibitory signals integrate to control liver regeneration remains
poorly understood. A screen for antiproliferative factors repressed after liver injury identified transducer of ErbB2.1 (Tob1), a member of the PC3/BTG1 family of mito-inhibitory
molecules as a target for further evaluation. Tob1 protein decreases after 2/3 hepatectomy
in mice secondary to posttranscriptional mechanisms. Deletion of Tob1 increases hepatocyte
proliferation and accelerates restoration of liver mass after hepatectomy. Down-regulation
of Tob1 is required for normal liver regeneration, and Tob1 controls hepatocyte proliferation in a dose-dependent fashion. Tob1 associates directly with both Caf1 and cyclindependent kinase (Cdk) 1 and modulates Cdk1 kinase activity. In addition, Tob1 has
significant effects on the transcription of critical cell cycle components, including E2F
target genes and genes involved in p53 signaling. We provide direct evidence that levels of
an inhibitory factor control the rate of liver regeneration, and we identify Tob1 as a crucial
check point molecule that modulates the expression and activity of cell cycle proteins.
CORRESPONDENCE
Seth J. Karp:
skarp@bidmc.harvard.edu
Abbreviations used: AAV-8,
adeno-associated virus 8; Cdk,
cyclin-dependent kinase; C/ebp, CCAAT enhancer binding
protein ; DRP, DNase-resistant
particle; eGFP, enhanced GFP;
LCB, lower confidence bound;
MUP, mouse urinary protein;
PAINT, promoter analysis and
interaction network toolset;
Socs3, suppressor of cytokine
signaling 3; Tob1, transducer of
ErbB2.1; TRE, transcriptional
response element.

Liver regeneration is controlled by a panoply of
factors performing diverse functions, including cytokine signaling (suppressor of cytokine
signaling 3 [Socs3], IL-6, and Tnf; Feingold
et al., 1988; Sakamoto et al., 1999; Zimmers et al.,
2003; Riehle et al., 2008), transcription (NF-b
and Stat3; Cressman et al., 1994, 1995), growth
factor response (egf [epidermal growth factor] and
TGF-; Russell, 1988; Jones et al., 1995), glucose metabolism (Bucher and Swaffield, 1975),
bile acid metabolism (Huang et al., 2006), and
platelet-derived signaling involving both extracellular nucleotides (Beldi et al., 2008) and serotonin
(Lesurtel et al., 2006). Advances in defining and
characterizing these signals leave unanswered the
fundamental question of how multiple inputs are
integrated into the discrete functional response of
hepatocyte proliferation after injury.
Restoration of liver mass requires stimulatory inputs. Inhibition or removal of IL-6, Stat3,
Egf, c-Jun, or serotonin, among others, delays
liver regeneration (Jones et al., 1995; Sakamoto
et al., 1999; Selzner and Clavien, 2000; Lesurtel
et al., 2006; Natarajan et al., 2007; Moh et al.,
K.J. Ho and N.L. Do contributed equally to this paper.
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2007). Furthermore, addition of a variety of
molecules, including IL-6, HGF (hepatocyte
growth factor), and thyroid hormone, enhances
liver regeneration (Francavilla et al., 1994; Ogura
et al., 2001; Zimmers et al., 2003).
Direct evidence that reduction in inhibitory
inputs is critical for restoration of liver mass after
injury has been more difficult to obtain, and this
remains a highly likely but poorly understood
paradigm. Clearly, inhibitory inputs must play
some role. For example, both TGF- and its
family member activin inhibit liver regeneration, and the activin antagonist follistatin enhances regeneration (Jakowlew et al., 1991;
Schwall et al., 1993; Kogure et al., 1995). These
experiments, however, which were performed
with pharmacologic doses of the molecules, do
not identify the actual mediator. Furthermore,
both TGF-1 and activin A are increased after
partial hepatectomy, making it difficult to conclude that either molecule inhibits regeneration
© 2010 Ho et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after
the publication date (see http://www.rupress.org/terms). After six months it is
available under a Creative Commons License (Attribution–Noncommercial–Share
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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after hepatectomy (Ueda et al., 2003; Takamura et al., 2005;
Michalopoulos, 2007). Similarly, although mice with deletions
in Socs3 or p21 exhibit enhanced liver regeneration, both are
induced after hepatectomy, suggesting they are not direct inhibitors of hepatocyte proliferation (Stepniak et al., 2006; Riehle
et al., 2008). Other candidate inhibitors of hepatocyte proliferation, including p27 and CCAAT enhancer binding protein 
(C/ebp-), are difficult to study because of baseline size or metabolic abnormalities in null mice (Flodby et al., 1996; Hayashi
et al., 2003).
Constitutive repressors that control the rate of hepatocyte
proliferation may be defined by the following characteristics:
baseline concentrations that are decreased after hepatectomy,
enhancement of hepatocyte proliferation in mice with targeted deletion, and prevention of normal regeneration when
maintained at high levels. To find such molecules, we undertook a screen for genes that decrease after partial hepatectomy
and might have antimitotic activity.
We then focused on transducer of ErbB2.1 (Tob1) based
on our characterization of its expression pattern after hepatectomy and its known antiproliferative functions (Otu et al.,
2007). Initially identified by interactions with p185erbB2,
proteins in the Tob1 family regulate cell cycle (Matsuda et al.,
1996; Yoshida et al., 2000, 2003a). Nuclear localization and
phosphorylation are critical for Tob1 function, which occurs
via at least two distinct mechanisms (Suzuki et al., 2002;
Kawamura-Tsuzuku et al., 2004). The first is to influence
cyclin-dependent kinase (Cdk) activity by binding to Caf1, and
the second is to modulate mRNA degradation by regulating
the first step of the process, deadenylation (Ikematsu et al., 1999;
Tucker et al., 2001; Temme et al., 2004; Ezzeddine et al.,
2007; Nishida et al., 2007). In this paper, we show that Tob1
fulfills the criteria for a critical constitutive inhibitor of hepatocyte proliferation, and we provide evidence that Tob1 acts
as an integrative molecule to control the rate of hepatocyte
proliferation after hepatectomy by influencing the activity
and expression of cell cycle proteins.

RESULTS
Tob1 mRNA and protein levels decline
after partial hepatectomy
To determine how Tob1 mRNA levels change as liver mass is
restored, real-time PCR was performed on regenerating liver
after 2/3 hepatectomy in C57B/6 mice (Fig. 1 A). There is high
baseline Tob1 mRNA expression in the uninjured liver (time
0). Levels decline acutely but recover by 24 h, reaching baseline by 48 h after hepatectomy. At 6 and 12 h after hepatectomy, these differences were significant (n = 3–9 animals).
In contrast, no changes in Tob1 mRNA expression were observed in sham-operated control mice (unpublished data).
Nuclear localization and phosphorylation state of Tob1
were analyzed separately by Western blotting (Fig. 1 B). In
response to 2/3 hepatectomy, cytoplasmic protein levels of both
Tob1 and p-Tob1 decrease by 24 h, are nearly undetectable
by 36 h, and begin to recover by 72 h, reaching basal levels
by 144 h. Nuclear levels of Tob1 and p-Tob1 are generally
lower overall. Levels decline by 24 h after hepatectomy and,
by 36 h, are nearly undetectable. Recovery begins by 144 h after
injury. Purity of cytoplasmic and nuclear fractions was verified
by blotting for -actin (cytoplasmic) and histone H3 (nuclear),
which also served as loading controls. No changes in Tob1
protein expression occurred in sham-operated mice (unpublished data). Collectively, our results suggest that Tob1 protein
decreases after hepatectomy, primarily via posttranscriptional
mechanisms. Because the proportion of Tob1 that is phosphorylated does not change dramatically over time, decreases
in levels of p-Tob1 are likely a result of protein degradation
and not dephosphorylation.
Liver regeneration after partial hepatectomy is accelerated
in Tob1-null mice.
To determine the functional consequences of loss of Tob1,
comparisons were made between WT and Tob1-null mice.
Western blot analysis confirmed disruption of the Tob1 gene
indicated by undetectable levels of Tob1 protein, which is
consistent with published results (Yoshida et al.,
2000, 2003a; and not depicted). Adult Tob1-null
mice and their WT littermates demonstrate similar
baseline liver/body weight ratio, exhibit similar minimal baseline hepatocyte proliferation as measured

Figure 1. Tob1 mRNA expression and protein levels
are decreased after 2/3 hepatectomy. (A) Real-time PCR
of Tob1 mRNA in liver samples at various intervals after hepatectomy. *, P = 0.05; **, P = 0.001. Each time point consists
of at least three and as many as nine animals. Error bars in
this and all other figures are standard error. (B) Western blot
analysis of total and phosphorylated Tob1 protein in whole
cell and nuclear extracts at various times after 2/3 hepatectomy. -Actin demonstrated the purity of the cytoplasmic
fraction, whereas histone H3 demonstrated the purity of the
nuclear fraction. Both serve as loading controls. All blot lanes
are the most representative sample from among at least
three different animals.
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Figure 2. Loss of Tob1 enhances liver
regeneration and hepatocyte proliferation
after hepatectomy. (A) 2/3 hepatectomy was
performed on Tob1-null and WT mice. Restoration of liver mass was measured by liver/
body weight (bw) ratio at the indicated time
points. n = 3–6 per time point. *, P = 0.03;
**, P = 0.001. (B and C) BrdU incorporation in
the liver at indicated time points after 2/3
hepatectomy. n = 3–6. *, P < 0.001; **, P = 0.008;
***, P = 0.01; ****, P = 0.007. Bar, 150 µM.

by BrdU labeling, and have similar histology (Fig. 2 A and
not depicted). After partial hepatectomy, Tob1-null mice
demonstrate a faster recovery of liver/body weight ratio
beginning at 72 h and continuing through 96 h (Fig. 2 A;
n = 3–6). Liver/body weight ratios are equivalent 9 d after
partial hepatectomy when the ratio returns to normal. Tob1-null
mice demonstrate more rapid onset of hepatocyte proliferation and higher absolute percentage of proliferating hepatocytes from 36 to 96 h after hepatectomy compared with WT
littermates (Fig. 2, B and C; n = 3–6). These results demonstrate that Tob1 functions to decrease the pace of regeneration after hepatectomy.
Mouse urinary protein (MUP)–Tob1–adeno-associated
virus 8 (AAV8) expresses Tob1 protein in the liver
We next investigated whether hepatocyte proliferation rates
depend on Tob1 protein levels. To answer this question,
it was necessary to develop a system in which Tob1 protein
levels could be precisely manipulated. To accomplish this, we
assembled an AAV8 with an MUP promoter to drive Tob1
expression in the liver (MUP-Tob1-AAV8; Ho et al., 2008).
To determine the time course of expression of Tob1 in
mice injected with MUP-Tob1-AAV8, Western blotting was
performed at different times after injection (Fig. 3 A). 1 wk
after injection, there was no difference between Tob1 protein levels in control mice who received no virus (NaCl), a
control virus containing enhanced GFP (eGFP; MUP-eGFPAAV8), or the MUP-Tob1-AAV8. By 2 wk after injection,
JEM VOL. 207, June 7, 2010

Tob1 expression in mice receiving
MUP-Tob1-AAV8 was robust and
above the level of mice receiving no
virus or MUP-eGFP-AAV8. As expected from the use of the MUP promoter to drive Tob1 expression, Tob1
protein expression was maintained
through 48 h after hepatectomy
(Fig. 3 A, *). Tob1 expression was
maintained through 3 wk after injection
(unpublished data). Each band shown
is the most representative band from
among three separate animals. These
data show that MUP-Tob1-AAV8 efficiently expresses recombinant protein
2 wk after injection. They also demonstrate that expression from the MUP promoter is high enough
to overcome any degradation mechanisms after hepatectomy.
Tob1 levels control the rate of hepatocyte proliferation
after partial hepatectomy
To precisely manipulate Tob1 levels, we performed reconstitution experiments in which Tob1-null mice were infected
with MUP-Tob1-AAV8 so that the only source of Tob1
would be the virus. To determine optimal dosing of the virus,
we noted that immunofluorescence for eGFP demonstrated
that 5 × 1010 DNase-resistant particles (DRPs) of MUP-eGFPAAV8 produces protein expression in 90% of hepatocytes,
whereas at 2.5 × 1010 DRP, 50% of hepatocytes express (unpublished data). These doses were used for MUP-Tob1-AAV8.
As the amount of virus was increased, proliferation rates decreased 48 h after hepatectomy (Fig. 3 B). Mice receiving 5 × 1010
DRP of MUP-Tob1-AAV8 demonstrated lowest proliferation of hepatocytes after hepatectomy, whereas mice with
2.5 × 1010 DRP MUP-Tob1-AAV8 or 5 × 1010 DRP control
MUP-eGFP-AAV8 virus exhibited progressively higher levels
of hepatocyte proliferation (P < 0.05 between all groups). To
verify that Tob1 protein levels decrease in the predicted fashion, Western blotting was performed on liver lysates prepared
from specimens at 48 h (Fig. 3 C). 5 × 1010 DRP of virus produced the highest amount of Tob1 protein, whereas 2.5 × 1010
DRP produced a lower level. These results demonstrate that
Tob1 levels control the rate of hepatocyte proliferation after
hepatectomy in a dose-dependent fashion.
1199

Figure 3. MUP-Tob1-AAV8 virus inhibits hepatocyte proliferation after hepatectomy in a dosedependent fashion. (A) Western blot of mouse liver
after injection of MUP-Tob1-AAV8, MUP-eGFP-AAV8,
or NaCl. The asterisk denotes Tob1 expression maintained even 48 h after hepatectomy and 2 wk after
injections. (B) Tob1-null mice were infected with
indicated doses of MUP-Tob1-AAV8 virus or MUPeGFP-AAV8 (control). 3 wk later, 2/3 hepatectomy
was performed and livers analyzed 48 h after hepatectomy. BrdU labeling is shown. n = 3. *, P = 0.01;
**, P < 0.05. (C) Western blot of Tob1 in whole cell
lysates. -Actin is used to demonstrate equal protein
loading. All blot lanes are the most representative
sample from among at least three different animals.

Effect of Loss of Tob1 on kinase activity
Tob1 associates with a variety of proteins and has multiple
functions including a critical role in early G1 progression
(Matsuda et al., 1996; Yoshida et al., 2000, 2003a). In particular,
Tob1 modulates Cdks via interaction with Caf1 to influence
cell cycle progression (Ikematsu et al., 1999; Nishida et al., 2007).
To determine whether modulation of Cdk1 activity might explain the effect of Tob1 on liver regeneration, we performed
kinase assays in WT mice, Tob1-null mice, and Tob1-null mice
with MUP-Tob1-AAV8 or control MUP-eGFP-AAV8 virus.
Consistent with this hypothesis, compared with WT mice, hepatic Cdk1 kinase activity was increased in Tob1-null mice. This
activity was reduced to normal levels with the introduction of
MUP-Tob1-AAV8 to the Tob1-null mice (Fig. 4 A, Tob1 null:
174 ± 17.9; Tob1 null with MUP-Tob1-AAV8: 117.4 ± 13.4;
Tob1 null with MUP-eGFP-AAV8: 180.2 ± 13.1; WT C57B/6:
118.75 ± 9.75; n = 4–6, P = 0.035 and P = 0.036). These
results suggest that Tob1 modulates cell cycle progression by
inhibiting Cdk1 kinase activity.
Tob1 and Caf1 associate with the cyclin–cdk complex
To further elucidate the mechanism of action of Tob1, we
tested whether Tob1 and Caf1 associate with the cyclin–cdk
complex in the liver. To accomplish this, multiple coimmunoprecipitation experiments were performed. Using antibodies
to Cdk1, both Tob1 and Caf1 were precipitated. Similarly,
antibodies to Tob1 coimmunoprecipitated both Cdk1 and Caf1.
Finally, antibodies to Caf1 coimmunoprecipitated Cdk1 and
Tob1 in normal adult liver (Fig. 4 B). Negative controls in-

cluded both a rabbit and a mouse IgG. Positive control lanes
consisted of whole cell lysates (unpublished data). These results demonstrate that all three proteins colocalize in a common complex. Our data provide mechanistic support for the
hypothesis that Tob1 modulates Cdk activity by direct association with the cyclin–cdk complex.
Effect of loss of Tob1 on pathways critical
for liver regeneration
To place Tob1 in the context of the many factors known to
be involved in liver regeneration, we performed several studies
of the effect of Tob1 deletion on other genes. We first studied
how loss of Tob1 affected the cell cycle proteins cyclin D1
and A2. Cyclin D1 is important for initiation of DNA synthesis, whereas cyclin A2 drives the transition to mitosis from
S phase (Malumbres and Barbacid, 2009). At baseline, mRNA
for cyclin D1 is increased in Tob1-null compared with WT
mice (n = 3; Fig. 5 A). Although there are no significant
changes in cyclin A2 mRNA expression in the Tob1-null
mice compared with WT mice, protein levels of both cyclins
increase faster in the Tob1-null mice (Fig. 5 B). In particular,
cyclin D1 is increased more strongly by 24 h continuing
through 36 h, whereas cyclin A is more robustly expressed by
24 h. These results show that Tob1 inhibits cyclin D1 expression at baseline and acts to delay the rise in both cyclin D1
and A2 necessary for cell division. Therefore, after hepatectomy, decreases in Tob1 would be expected to allow increases in cyclin D1 and A2 that are necessary for normal
hepatocyte proliferation.
Figure 4. Loss of Tob1 results in increases in Cdk1 activity, and Tob1 and
Caf1 bind to Cdk1. (A) Cdk1 kinase activity
in the liver of Tob1-null mice infected or not
with MUP-Tob1-AAV8 or MUP-eGFP-AAV8.
n = 4–6. *, P = 0.035; **, P = 0.036. (B) Coimmunoprecipitation of Cdk1, Tob1, and Caf1.
IP, immunoprecipitation antibodies; IB, immuno
blot antibodies. Mouse IgG control is the negative control. The samples were run on the
same gel and each lane is the most representative among three samples.
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Figure 5. Cyclin D1 and A2 expression increase more quickly in Tob1-null mice compared with WT controls. (A) Real-time PCR of cyclin D1
and cyclin A2 mRNA at indicated time points after hepatectomy. Each point represents at least three mice. *, P = 0.012. (B) Cyclin D1 and A2 protein was
measured by immunoblot at indicated time points after hepatectomy. -Actin was the loading control. All lanes are the most representative of three separate animals. Each row was run on the same gel, and the break represents portions of the gel not shown.

We next investigated the effect of loss of Tob1 on cytokine signals Socs3 and IL-6. Both are up-regulated soon after
partial hepatectomy and are critical for liver regeneration
(Zimmers et al., 2003; Riehle et al., 2008). No change was
observed in the mRNA expression of either of these molecules in WT mice versus Tob1-null mice over the initial 48 h
after hepatectomy (Fig. S1). Both exhibit an acute rise by 6 h
after injury. These results suggest that Tob1 does not act by
affecting cytokine transcription.
IL-6 is essential for Stat3 activation via phosphorylation and
nuclear translocation (Cressman et al., 1994; Zimmers et al.,
2003). To determine if Tob1 influences this pathway, we examined Stat3 protein levels, phosphorylation, and nuclear localization in Tob1-null and WT mice. Stat3 protein levels are
fairly constant and not dramatically different between Tob1null and WT littermates, with the exception that nuclear
Stat3 is higher in WT mice than in Tob1-null mice at baseline, and nuclear Stat3 increases more robustly in Tob1-null
mice than in the WT after hepatectomy (Fig. 6). In contrast,
p-Stat3 is present in both cytoplasmic and nuclear fractions of
quiescent adult liver from Tob1-null mice but not in WT littermates (Fig. 6, ^ vs. *). In both Tob1 and WT mice, Stat3
undergoes dramatic activation with markedly increased phosphorylation by 6 h after hepatectomy. These results suggest that
at baseline, Tob1 helps to suppress hepatocyte proliferation by
suppressing Stat3 phosphorylation and therefore its activation.
Repression of p21 activity is required for hepatocyte proliferation after hepatectomy (Stepniak et al., 2006). To determine the effect of loss of Tob1 on p21, we examined mRNA
and protein expression in Tob1-null mice compared with WT
littermates. p21 mRNA is induced in both Tob1-null and WT

normal adult mice and at 6, 24, and 48 h after hepatectomy (unpublished data). Despite baseline p21 levels being higher in
Tob1-null mice, nuclear and cytoplasmic p21 levels increase in a
similar fashion in WT and Tob1-null mice (Fig. 6). The presence
of Tob1, therefore, serves to suppress p21 levels at baseline.
p27 is a negative regulator of cell cycle, and p27-null mice
accelerate DNA replication after partial hepatectomy (Hayashi
et al., 2003). To determine whether Tob1 influences p27,
mRNA and protein levels were examined. Loss of Tob1 has
no effect on p27 mRNA levels after hepatectomy. p27 protein
levels are slightly higher at baseline in Tob1-null mice than in
the WT (Fig. S2). These results suggest that Tob1 functions to
suppress p27 levels at baseline.
C/ebp- functions as an inhibitor of hepatocyte proliferation and newborn mice lacking C/ebp- exhibit increased
hepatocyte proliferation (Flodby et al., 1996). There were no
differences in mRNA levels between Tob1-null mice and WT
mice. In contrast, Tob1-null mice demonstrated accelerated loss
of C/ebp- protein after hepatectomy compared with WT
mice (Fig. 7). These results suggest that Tob1 tends to maintain
C/ebp- protein levels via posttranscriptional mechanisms.
Tob proteins bind to Smad1, 5, and 8, preventing their
activity as a transcription factors, and may have a role in their
translocation to nuclear bodies (Yoshida et al., 2003b; Ross
and Hill, 2008). To determine whether loss of Tob1 affects
mRNA or protein levels for these Smads, real-time PCR and
Western blotting were performed. Loss of Tob1 has no effect
on mRNA for Smad1 (see Fig. 9 A). In contrast, loss of Tob1
blocks the robust induction of Smad5, which occurs in WT
mice after 2/3 hepatectomy (n = 3; Fig. 8 A), and loss of
Tob1 leads to generally higher levels of Smad8 mRNA after
Figure 6. Loss of Tob1 affects expression of proteins
important for restoration of liver mass after injury.
Total and phosphorylated Stat3 and p21 in the liver of
Tob1-null mice and WT littermates was measured by
immunoblot at indicated time points after hepatectomy.
-Actin and histone H3 were loading controls for the
cytoplasmic and nuclear extracts, respectively. Note the
presence of p-Stat3 in quiescent adult liver from Tob1null mice but not in WT littermates (^ vs. *). All samples
were run on the same gel and each lane is the most representative among three samples.
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Figure 7. Effect of loss of Tob1 on C/EBP-. (A) C/EBP- mRNA was measured by real-time PCR in the liver of Tob1-null and WT littermates at indicated time points after hepatectomy. n = 3. P = NS. (B) C/EBP- protein was measured by immunoblot. -Actin was the loading control. All lanes are the
most representative of three separate animals.

hepatectomy (n = 3). Nuclear Smad protein levels are generally
lower in Tob1-null mice. Because Smad signaling occurs via
phosphorylation and nuclear localization, a better measure of
the action of Tob1 on Smad signaling is to look at activation.
In this case, nuclear levels of phosphorylated Smads are remarkably similar between Tob1-null mice and their littermates. Interestingly, Smad activation decreases dramatically
by 24 h after hepatectomy in both Tob1-null and WT mice
(Fig. 8 B). This data suggests that although Tob1 has effects
on Smad mRNA transcription and protein levels, Tob1 does
not directly impact Smad activation.
Absence of Tob1 affects expression of genes involved
in a variety of pathways
To provide further insight into how loss of Tob1 enhances
liver regeneration after partial hepatectomy, we performed
microarray analysis of samples from WT and Tob1-null mice
as normal adults and 24 h after 2/3 hepatectomy. Each experimental point (e.g., WT at 24 h after hepatectomy) used
data from two chips, each with a different set of three pooled
animals. Each chip was run in duplicate. Affymetrix 2.0
chips containing >45,000 oligonucleotides were used. The full
dataset is available from GEO under the accession number
GSE21836.
Analyzing the effect of deletion of a specific gene using
microarray data can be performed in several ways to answer
different questions. To maximize the relevance of the conclusions, we reasoned as follows: Tob1 loss is the critical event in
accelerating hepatocyte proliferation and restoration of liver

mass. Tob1 levels decrease after hepatectomy in WT mice, so
that Tob1-null mice can be considered to have an accelerated
loss of Tob1. Because Tob1 has no effect on baseline hepatocyte proliferation and there is a clear effect by 36 h, we chose
24 h to analyze, a time between these points which we reasoned would give enough time for transcriptional differences
to become apparent.
To perform this analysis, we constructed a list of genes
significantly changed in the WT compared with normal adult
liver after hepatectomy and a separate list of genes significantly
changed in the Tob1-null mice 24 h after partial hepatectomy
compared with uninjured livers from Tob1-null mice. We arranged these in a Venn diagram and chose only genes significantly changed in the Tob1-null and not in the WT mice for
further analysis.
We chose a threshold for differential regulation as a
lower confidence bound (LCB) > |1.2| (see Irizarry et al.,
2003 and Otu et al., 2007 for algorithms and methods).
This was chosen because the LCB is a stringent estimate of
differential expression and most likely corresponds to an actual difference of >1.2. This level was chosen prospectively
as the most accurate choice for reliable differential expression. Using this threshold, there were 616 genes induced in
the Tob1-null mice at 24 h after hepatectomy that were not
induced in the WT mice at this time point. We note 969
genes are induced in the WT mice that were not induced in
the Tob1-null mice after hepatectomy.
To validate this entire dataset, a total of 20 genes were
interrogated using real-time PCR. Examining each gene in
Figure 8. Loss of Tob1 does not change
Smad activation. (A) Smad1, Smad5, and
Smad8 mRNA was measured by real-time PCR
in the liver of Tob1-null (KO) and WT (WT)
mice at different times after hepatectomy
(n = 3; *, P = 0.001) and increased Smad8
expression at 24 h (n = 3; **, P = 0.01). Each
point represents at least three mice. (B) Total
and phosphorylated Smad 1/5/8 protein was
measured by immunoblot in nuclear extracts
of Tob1-null mice. -Actin and histone H3
immunoblots demonstrate purity of the nuclear extracts and serve as a loading control.
All lanes are the most representative of three
separate animals.
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both WT and Tob1-null mice between 0 and 24 h generated 40 relationships that could be characterized as increased,
decreased, or not changed. For the array data, an LCB > |1.2|
was considered a change, whereas for the real-time PCR
data, a p-value of <0.05 was considered a change. In 34 of
these 40 (85%), the real-time data and the array data were
concordant (Fig. S3).
We next identified networks differentially regulated in the
Tob1-null mice compared with WT mice. This type of analysis
is complementary to individual gene information and may be
more robust because it examines many genes to identify biological processes. To accomplish this, a score was generated (Ingenuity Systems software) that takes into account the number of
genes in the network and the size of the network. It allows a calculation of the approximate fit between each network and the
genes from the input dataset, allowing the network to be ranked.
The score is a p-value calculation to determine the possibility
that the network shown could be found by random chance.
Analysis of this set of genes, in which expression changed between 0 and 24 h after hepatectomy in the Tob1-null mice but
not in WT mice, allowed identification of pathways affected by
loss of Tob1. We limited our analysis to pathways with P < 0.01,
given the large number of pathways and genes examined. 20
pathways were identified in this manner. The most significant
pathway affected was p53 signaling (Fig. 9), with P < 106,

followed by insulin-like growth factor 1 signaling, with
P = 0.00004. The full dataset can be found in Table S2.
Loss of Tob1 influences transcriptional pathways
To better understand the transcription factors and pathways affected by the loss of Tob1, we used promoter analysis and interaction network toolset (PAINT). This algorithm takes an input
set of genes, in our case the genes differentially expressed in the
Tob1-null mice, and identifies transcriptional response elements
(TREs) in the flanking or known promoter regions of the input
gene list that are predicted to bind to known transcription factors. In this way, PAINT helps form a picture of which of a
smaller number of genes (the transcription factors) are responsible
for the larger number of changes in gene expression patterns.
Using our dataset, this analysis identified several transcription
factors expected to bind to these regions, including Ets-1,
FoxD3, Cre-BP1, E2F, and c-Jun (Table S1). This is evidence
that these transcription factors play a role in many of the gene
expression patterns observed in the Tob1-null mice. Because
E2F targets are important for many cellular processes, including
cell cycle regulation, we then looked at these genes by category
according to the gene list generated by Bracken et al. (2004; Fig.
S4). To determine which of these are predominately affected by
loss of Tob1, our input list included only genes induced in Tob1null mice but not WT mice at 24 h. Analysis of this list revealed
that most were involved in DNA replication. These results suggest that the
presence of Tob1 inhibits E2F targets
responsible for S phase.

Figure 9. Gene interaction networks
affected by loss of Tob1. A dataset of genes
regulated in the Tob1-null mice (LCB > |1.2|),
but not in WT mice, was used to determine
how loss of Tob1 affects gene expression after
2/3 hepatectomy. From this gene list input, a
score was determined that ranks networks
according to how relevant they are to the
genes in the input dataset (see Results). The
score for the p53 network was 34, the negative exponent of the p-value (P = 1034), and
this network is shown here. Each gene is
given a heat map color that corresponds to
the degree of regulation; reds are increased
and greens are decreased, both in proportion
to the intensity of the color. Numbers represent fold change. Shapes denote function as
follows: trapezoids, transporters; diamonds,
enzymes; ovals, transcription regulators; triangles, kinases; rectangles, ion channels; double circles, complex; circles, other. Arrows
denote the first molecule acts on the second,
and perpendicular lines denote the first inhibits the second. Solid lines are direct interactions, and dashed lines are indirect
interactions. Data are from two distinct chips,
each with three different animals.
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DISCUSSION
We hypothesized that repression of inhibitory signals was a
key mechanistic paradigm during liver regeneration. To test
this postulate, a screen was undertaken for genes that might
be constitutive inhibitors of liver regeneration, i.e., repressed
after liver injury. The antiproliferative molecule Tob1, a member of the PC3/BTG1 family of antiproliferative molecules,
was identified as potentially fulfilling these requirements.
Our major findings are that Tob1 acts as a constitutive
repressor of hepatocyte proliferation after hepatectomy. Tob1
protein levels decrease after hepatectomy, most likely as a result of protein degradation. Decreased Tob1 is necessary for
normal liver regeneration, as the rate of hepatocyte proliferation is determined by endogenous Tob1 levels. Tob1 suppresses
Cdk1 kinase activity and associates with Caf1 in the Cdk complex. Further antiproliferative activities of Tob1 are likely a
result of effects on a variety of cell cycle proteins, including the
suppression of cyclin D1 and A2 and inhibition of E2F targets
concerned with DNA synthesis.
These results are important for several reasons. Demonstrating that levels of an inhibitory protein control the rate of
hepatocyte proliferation after hepatectomy support a novel paradigm in liver regeneration in which inhibitory factors must be
actively suppressed for normal regeneration. This model is difficult to prove explicitly without reconstituting the gene in
the null mouse. Our AAV-8 construct provides this functionality and allows us to show that the proliferation rate depends
directly on Tob1 levels. These results are in contrast to work
with, for example, Socs3 and p21 (Stepniak et al., 2006; Riehle
et al., 2008). In these cases, although null mice for either demonstrate enhanced liver regeneration, protein levels actually increase after hepatectomy, suggesting that their effect is indirect.
Two major findings point to a mechanism of action for
Tob1. The first is that Tob1 binds to Caf1 within a complex
with Cdk1. Cdk1 is a critical Cdk activated by cyclin A and
then cyclin B to facilitate mitosis (Malumbres and Barbacid,
2009). To determine the nature of this interaction, we examined kinase activity in the Tob1-null mice. Increased kinase
activity in Tob1-null mice suggests that Tob1 acts to inhibit
kinase activity, delaying cell cycle progression.
A defining aspect of Tob1 is that it seems to be a multifunctional protein involved in a variety of cellular processes. In addition to its effect on kinase activity, we note that loss of Tob1
influences the transcription of multiple genes important for cell
cycle progression. Loss of Tob1 accelerates the rise in cyclin D1
and A2 protein levels. In a similar fashion, loss of Tob1 accelerates the rise in E2F targets, preferentially affecting those important for DNA synthesis. Collectively, these results suggest that
Tob1 represses the transcription of genes important for cell cycle
progression. How Tob1 acts to do this is unclear. It is possible
that a wide-ranging effect of Tob1 on RNA degradation might
be responsible for effects on these multiple target genes. Alternatively, Tob1 might directly affect a few transcription factors, for
example, E2F, with multiple downstream effects.
Other antiproliferative proteins that may regulate cell cycle
are influenced by loss of Tob1. These include p21, which sup1204

presses increases in PCNA, cyclins, and cdk2-associated kinase activity, p27, which inhibits cell cycle progression, and
C/ebp-, which interacts with the cyclin–Cdk complex
(Albrecht et al., 1998; Greenbaum et al., 1998; Wang et al.,
2001; Kossatz et al., 2004; Weymann et al., 2009). Increased
levels of p21 and p27 observed in Tob1-null mice suggest that
these antiproliferative proteins may be responding to or compensating for a primed hepatocyte to prevent proliferation.
Contrast this with the more rapid decrease in C/ebp- in
Tob1-null mice, suggesting that Tob1 helps maintain C/ebp-.
It is tempting to suggest, therefore, that Tob1 and C/ebp-
are regulated along the same molecular signaling pathway,
whereas p21 and p27 may be part of a separate pathway.
Dysregulation of p53 signaling identified by array analysis
suggests an additional mechanism for Tob1 in cell cycle progression. p53, an important tumor suppressor, can initiate cell
cycle arrest during times of stress (Boehme and Blattner, 2009).
In addition, there is an additive effect on tumorigenesis when
p53 and Tob1 are simultaneously deleted (Yoshida et al., 2003a).
Collectively, these and our results place Tob1 as a possible mediator of p53 activity on the cell cycle.
Temporally, major changes in Tob1 protein levels occur
after cytokine up-regulation in response to hepatectomy. It is
therefore not surprising that loss of Tob1 has minimal effects
on mRNA for either IL-6 or Socs3. Our findings that both
are increased after hepatectomy are consistent with published
data (Sakamoto et al., 1999; Campbell et al., 2001). IL-6 promotes Stat3 activation and Socs3 is part of a negative-feedback
loop to inhibit Stat3 activation. We find, consistent with
published results, that Stat3 is activated after hepatectomy
(Cressman et al., 1994; Zimmers et al., 2003; Riehle et al.,
2008). In addition, our finding that Stat3 is activated even in
quiescent livers in Tob1-null mice suggests that Tob1 may
influence cytokine signaling not by influencing cytokine
transcription but rather at the signal transduction level.
Tob1 binds to the downstream effectors of Bmp signaling, including Smad1, 5, and 8, and promotes their localization to the nucleus (specifically the nuclear bodies), which
may result in the suppression of their activity. BMP signals
are transduced by Smad phosphorylation and nuclear translocation (Feng and Derynck, 2005). Although Smad protein
levels and mRNA are altered in Tob1-null mice, are no
changes in the level or phosphorylation of Smads in WT versus Tob1-null mice, arguing that Tob1 does not have a direct
effect on Smad signaling.
Tob1 affects the transcription of targets of the transcription factors Ets-1, FoxD3, Cre-BP1, E2F, and c-Jun. Ets-1
binds to a portion of the p53 promoter and may regulate its
signaling (Baillat et al., 2009). FoxD3 is important for regulating endodermal-specific promoters (Guo et al., 2002).
Cre-BP1 forms a homodimer or heterodimer with c-Jun and
stimulates CRE-dependent transcription. Identification of
both Cre-BP1 and c-Jun TREs in genes dysregulated in
Tob1-null mice is particularly interesting because c-Jun, a member of the AP-1 complex, is necessary for liver regeneration
by repressing p53/p21 and p38 MAPK (Stepniak et al., 2006).
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The specific interaction between Tob1 and c-Jun remains
unknown but potentially important.
Importantly, our data show that although Tob1 levels
control the rate of hepatocyte proliferation, Tob1 does not
ultimately control liver size. At baseline, livers in Tob1-null
mice are normal size, and by 9 d after hepatectomy, livers in
Tob1-null mice again return to normal size. In our hands,
hepatocyte proliferation after hepatectomy begins >24 h after
surgery and peaks at 48 h. Although there are studies indicating that peak proliferation occurs earlier, our results are consistent with those of others (Lesurtel et al., 2006).
When analyzing our array data, we used a cutoff for differential expression of an LCB of |1.2|. This was chosen as a
stringent estimate and the actual difference in expression is
likely much higher than this (Ramalho-Santos et al., 2002;
Wang et al., 2006). In fact, choice of this cutoff was validated
by extensive real-time data showing 85% concordance with
the array data. Given the intrinsic limitations of these methods
to corroborate each other as a result of alternative splicing,
normalization choices, and the difficulty arrays have in detecting low abundance transcripts, this concordance is consistent
with other studies (Wang et al., 2006).
In summary, these results suggest a model in which Tob1
antagonizes proliferative signals and directly suppresses cell
cycle progression by binding to and modulating Cdk activity
and inhibiting transcription of multiple proteins critical for cell
cycle progression. These findings demonstrate that an inhibitor of proliferation must be blocked or suppressed for normal
liver regeneration. Restoration of liver mass after hepatectomy
is therefore best thought of as a balance between stimulatory
and inhibitory factors. In human diseases in which liver function and regeneration are suppressed, it may be that understanding this pathway could point to therapeutic modalities.
MATERIALS AND METHODS
Mice. Tob1-null mice on a C57BL/6 background were a gift from I. Bagchi
(University of Illinois at Urbana-Champaign, Champaign, IL). These mice are
derived from a line produced and maintained by T. Yamamoto (University of
Tokyo, Tokyo, Japan; Yoshida et al., 2000). As described previously, Tob1deficient mice are predisposed to spontaneous tumor development in the liver
and elsewhere (Yoshida et al., 2003a). Viral constructs work best in male mice;
thus, all mice used in this study were male between 7 and 10 wk of age. Genotyping was performed as previously described (Yoshida et al., 2003a).
2/3 hepatectomy. All surgeries were performed according to the National
Institutes of Health guidelines for the humane treatment of laboratory animals and with approval of the Harvard Institutional Animal Care and Use
Committee. Mice were anesthetized with 60 mg/kg ketamine (Hospira) and
7 mg/kg xylazine (Phoenix Pharmaceuticals) and positioned supine. A transverse incision was made inferior to the xiphoid process, which was excised.
The median and left lateral lobes of the liver were eviscerated and ligated. At
tissue recovery, mice were anesthetized and weighed. Livers were excised,
rinsed, blotted, and weighed. Sections were snap frozen in liquid nitrogen,
fixed in 10% neutral buffered formalin, or preserved in RNALater (QIAGEN).
Mortality was <5% and not associated with a particular genotype.
AAV8 vector production: subcloning and packaging. A 2,300-bp murine Tob1 cDNA was obtained from the American Type Culture Collection.
The 1,090-bp coding sequence was reframed via PCR to eliminate the untranslated regions and provide new flanking restriction sites and an optimized
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Kozak sequence. The PCR product was cloned into pAMP, an AAV2 vector
plasmid in which expression is controlled by the highly specific MUP promoter element (Ho et al., 2008). An AAV2-MUP-eGFP vector plasmid was
constructed as a negative control. Both vectors were cross-packaged in AAV8
via triple plasmid transfection into AAV-293 cells (Agilent Technologies). No
helper virus was used. In brief, each AAV vector plasmid, an AAV2/8 rep/
cap plasmid providing AAV2 replicase and AAV8 capsid functions, and a
third plasmid encoding adenovirus helper functions, pHelper (Agilent
Technologies), were cotransfected into 293 cells at a molar ratio of 1:1:1.
Cells were harvested 48 h after transfection. Cell pellets were resuspended
in DME, and intracellular virus particles released by three consecutive
rounds of freeze-thaw, followed by centrifugation at 13,000 rpm for 10 min
to remove particulates. Vector stocks were stored at 80°C and titered
by real-time PCR using an ABI Prism 7700 Sequence Detection system
(Applied Biosystems).
Virus injections. MUP-Tob1-AAV8, MUP-eGFP-AAV8 (negative control), or vehicle (saline) was administered via tail veins as previously described
(Ho et al., 2008). Injections were performed at 200 µl for a total dose of either
5 × 1010 DRP or 2.5 × 1010 DRP. These amounts were chosen based on a
linear relationship between MUP-eGFP-AAV8 injection amounts and fluorescence at this dose. 2/3 hepatectomies were performed at the indicated
times after virus injections. Excised livers were rinsed in PBS and snap frozen
in liquid nitrogen or fixed in 10% neutral buffered formalin.
Immunohistochemistry. Staining for BrdU (BD) was performed on fixed
paraffin-embedded liver sections according to the manufacturer’s instructions
(rat ABC Staining System; Santa Cruz Biotechnology, Inc.). Primary antibody was rat anti–mouse BrDU (Santa Cruz Biotechnology, Inc.). Proliferation index was quantified as the percentage of labeled hepatocyte nuclei that
stained with BrdU over at least three high-power fields (400×).
mRNA isolation and real-time RT-PCR Total mRNA was purified
from 30 mg of liver tissue preserved in RNALater with the RNeasy Mini kit
(QIAGEN). 1 µg mRNA was reverse transcribed to cDNA using a High
Capacity cDNA Reverse Transcription kit (Applied Biosystems). An ABI 7700
Sequence Detector (Applied Biosystems) was used for all real-time PCR. cDNA
template was diluted 1:5 and amplified using inventoried Taqman gene expression assays (Applied Biosystems) under standard conditions. Gene expression
levels were normalized to GAPDH using the comparative CT method. Data
were analyzed using ABI Sequence Detector Software (Applied Biosystems).
Protein sample preparation, immunoprecipitation, and Western
blot analysis. Whole cell liver lysates were prepared by homogenizing 50 mg
of frozen liver tissue in lysis buffer (50 mM Tris, 100 mM NaCl, 5 mM
EDTA, 10% glycerol, and 0.5% NP-40) containing phosphatase inhibitor
(Thermo Fisher Scientific) and protease inhibitor cocktail (Roche). Samples
were sonicated for 30 s and clarified by centrifugation. Protein concentration
was determined with the DC assay kit (Bio-Rad Laboratories).
Nuclear and cytoplasmic fractions were prepared as previously described
(Andrews and Faller, 1991), with some modification: liver tissue was homogenized in hypotonic buffer (10 mM Tris, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
DTT, and 0.1% NP-40) containing protease inhibitor cocktail and cells were
allowed to swell on ice for 10 min. Nuclei were pelleted and the supernatant
containing the cytoplasmic fraction cleared. Nuclei were resuspended and
lysed with 1% NP-40 and the supernatant collected. Protein concentration
was determined with a BCA kit (Thermo Fisher Scientific). Enrichment
quality was determined by immunoblotting for -actin and histone H3. Protein was denatured and separated by SDS-PAGE in 10% Criterion XT Bis-Tris
precast gels (Bio-Rad Laboratories) and transferred to nitrocellulose (Millipore). All antibody dilutions were made in 5% milk in TBS buffer. Primary
antibodies used were the following: mouse monoclonal anti-Tob1 (Abcam),
rabbit anti-Smad1/5/8 (Santa Cruz Biotechnology, Inc.), mouse monoclonal anti-cyclin D1 (Santa Cruz Biotechnology, Inc.), rabbit anti-cyclin A2
(EMD), mouse monoclonal anti-actin (Sigma-Aldrich), goat anti-GAPDH
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(Santa Cruz Biotechnology, Inc.), rabbit anti-histone H3 (Millipore), mouse
monoclonal anti-Cdk1 (Abcam), rabbit anti-phosphoTob1 (Abcam), rabbit
anti-Caf1 (Santa Cruz Biotechnology, Inc.), rabbit anti-C/ebp-, rabbit
anti-Stat3, and mouse monoclonal anti-p21 (Santa Cruz Biotechnology, Inc.).
HRP-conjugated species-specific secondary antibodies were obtained from
eBioscience, Jackson ImmunoResearch Laboratories, Santa Cruz Biotechnology, Inc., or Promega. In some cases, membranes were stripped with stripping
buffer (Boston Bioproducts) according to the manufacturer’s instructions,
washed extensively, and then reblocked and reprobed.
Coimmunoprecipitation. Cell lysates were prepared using the NE-PER
cytoplasmic and nuclear extraction kit (Thermo Fisher Scientific). Lysate
preclearing and red protein G affinity gel bead preparation was accomplished
by washing 50 µl EZview red protein G affinity gel beads in 750 µl of iced
lysis buffer, followed by centrifugation for 30 s at 8,200 g and washing. Beads
were resuspended in 50 µl of cold lysis buffer. 500 µg of lysate was added to
the beads, incubated with gentle mixing for 1 h at 4°C, and centrifuged at
8,200 g for 10 min at 4°C, and the supernatant was retained. 5 µg of mouse
monoclonal anti-Cdk1 (Santa Cruz Biotechnology, Inc.), rabbit polyclonal
anti-Caf1 (Santa Cruz Biotechnology, Inc.), or mouse monoclonal anti-Tob1
(Abcam), or mouse monoclonal isotype control (Abcam) and rabbit isotype
control (Abcam) was used. Secondary antibodies were anti–rabbit IgG, HRPlinked antibody (Cell Signaling Technology), and anti–mouse TrueBlot
ULTRA: HRP-linked antibody (eBioscience).
Kinase assays. EZview red protein G beads, using the mouse monoclonal
anti-Cdk1 (Santa Cruz Biotechnology, Inc.) antibody as the initial immunoprecipitation antibody, were prepared as per the manufacturer’s instructions.
Kinase buffer, 10 mM ATP (Cell Signaling Technology), and Rb biotinylated peptide (Cell Signaling Technology) were combined with the equilibrated beads to a final reaction volume of 50 µl and the final concentration
of kinase buffer, 200 µM ATP, and 1.5 µM Rb peptide and incubated at
room temperature for 30 min. 50 µl of Stop buffer (50 mM EDTA, pH 8.0)
was added and 25 µl/well transferred to a 96-well streptavidin-coated plate
(PerkinElmer) with 75 µl ddH2O/well and incubated at room temperature for
60 min. Each well was washed, and 100 µl/well of rabbit polyclonal phospho-Rb antibody (Cell Signaling Technology; 1:1,000 dilution) was added
and incubated at room temperature for 120 min. Each well was washed, and
100 µl/well of anti–rabbit HRP-linked antibody (Cell Signaling Technology;
1:1,000 dilution) was added and incubated at room temperature for 30 min.
Each well was washed, and 100 µl/well of TMB substrate (Cell Signaling Technology) was added and incubated at room temperature for 15 min. 100 µl/
well of STOP solution (Cell Signaling Technology) was added to each well
and a SpectraMax M5 microtiter plate reader (MDS Analytical Technologies)
used to read the absorbance at 450 nm.
Microarray analysis. Each mRNA sample consisted of 10 µg of high-quality
total mRNA pooled from three animals and was run on an Affymetrix mouse
430 2.0 array as previously described (Otu et al., 2007). Two independent
chips, each loaded with a different set of three pooled animals, were examined
in duplicate. LCB of fold change was determined as previously described
(Otu et al., 2007). Genes with an LCB of >|1.2| were considered dysregulated in the Tob1-null mice. The LCB is a stringent estimate of the LCB of
the fold change (Irizarry et al., 2003; Otu et al., 2007).
Promoter analysis. PAINT (version 3.9; http://www.dbi.tju.edu/dbi/tools/
paint) was used to determine TREs in the promoter regions of genes regulated in Tob1-null mice, but not in WT mice, 24 h after hepatectomy as
compared with normal adult liver. Promoter regions were retrieved considering 5 kb upstream of the initiation codon. The number of gene identifiers
for which upstream sequences were found was 4,264, representing 2,829
unique promoters. The match filter was set to minimize false positives, the
TRE core similarity threshold was set at 1.00, and we included TREs found
on the complimentary strand. The output file contained a matrix of 159
transcription factors.
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Data analysis. All comparisons were performed using a two-tailed unpaired
Student’s t test. All statistical tests used at least three and as many as nine different samples for each time point and genotype. * in the figures denotes statistical significance as defined by P < 0.05. All error bars in the figures are
standard error.
Online supplemental material. Figs. S1 and S2 show mRNA or protein
expression patterns after hepatectomy in Tob1-null mice for three proteins
known to be important for liver regeneration: IL-6, Socs 3, and p27. Fig. S3
shows real-time PCR validation of 20 genes found to be regulated using
gene array analysis after hepatectomy in Tob1-null mice compared with
WT mice. Fig. S4 examines categories of E2F targets differentially induced
after hepatectomy in Tob1-null mice compared with WT mice. Table S1
shows transcription factors expected to bind to putative promoter regions
in the genes differentially induced 24 h after hepatectomy in Tob1-null
mice compared with WT mice. Table S2 shows pathways regulated differently after hepatectomy in Tob1-null mice compared with wild-type mice.
Online supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20092434/DC1.
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